Abstract: The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Abstract: Disclosed is an isolated binding protein including a cardiac troponin I (cTnI) antigen binding domain, and preparation and a use and the like of the binding protein. The antigen binding domain includes at least one complementarity determining region selected from an amino acid sequence defined in this article, or has at least 80% sequence identity with the complementarity determining region of the amino acid sequence and has KD?9.96×10?8 mol/L affinity with cTnI. The binding protein may be used in the detection field of the cTnI protein.

Abstract: The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast cancer. In some embodiments, the disclosure teaches novel antibodies that bind to filamin A. In some embodiments, the antibodies are intrabodies.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.

Abstract: The present disclosure relates to modified anti-TNF? polypeptides, compositions comprising modified anti-TNF? polypeptides, methods of making the same, and methods of using the modified anti-TNF? polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of inflammatory disorders using the modified anti-TNF? polypeptides.

Abstract: The present invention relates to a targeting module comprising a chemically synthesized peptide binding moiety specific for a human cell surface protein or protein complex, a kit comprising the targeting module and a vector or a cell comprising a nucleic acid encoding a universal chimeric antigen receptor and the use for the treatment of cancer, infections and autoimmune disorders.

Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: A method for restoring immune control over autoimmunity in a subject in need thereof is described. The method comprises the step of administering to the subject a therapeutically effective amount of an antibody that disrupts Siglec-binding in cis. A method of screening for an antibody that is disruptive of Siglec binding in cis, a method of making an antibody for restoring immune control over autoimmunity to a subject in need, a method of modulating autoimmunity in an immune cell and a method of releasing sialic acid binding site of human CD22 from cis-binding configuration to trans-ligand formation in treating autoimmunity in a subject in need thereof are also described. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also disclosed herein.

Abstract: Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.

Abstract: Disclosed herein are antibody molecules binding specifically to C-KIT, antigen-binding portions thereof and medical uses therefor.

Abstract: The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ?60%, ?70%, ?80%, or ?90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ?10 nM, ?5 nM, ?2.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Abstract: Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.

Abstract: Provided herein are antibodies that selectively bind to complex comprising a non-classical HLA-I (e.g. HLA-E) and a neoantigen having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) as disclosed herein, as well as methods and uses thereof.

Abstract: Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.

Abstract: The present invention relates to an anti-c-Met agonist antibody and use thereof, and more particularly, to an agonist antibody or fragment thereof that specifically binds to a human-derived c-Met protein, to a method for producing the same, to c-Met specific detection method using this, to a composition for preventing or treating cancer comprising the same, to a composition for inducing stem cell differentiation, and a culture medium for stem cells. The method of the present invention can be usefully used for detecting c-Met antibodies, inducing stem cell differentiation using the antibody, and treating or preventing cancer.

Abstract: The present disclosure relates to biotechnology and provides antibodies that specifically bind to IL-5R?. The disclosure also relates to DNA encoding the antibodies, the corresponding expression vectors and methods of production thereof, as well as methods of treatment using the antibodies.

Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Abstract: The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.

Abstract: Provided herein are common light chain bispecific antibodies that bind CD38 and CD19. The common light chain bispecific antibodies comprise an anti-CD38 heavy chain variable region and anti CD19 heavy chain variable region that each have a negatively-charged amino acid at a terminal heavy chain variable region position. The common light chain bispecific antibodies comprise further comprise an anti-CD38 heavy chain constant region and anti-CD19 heavy chain constant region that each lack a C-terminal lysine residue. Further provided are nucleic acids encoding such common light chain bispecific antibodies and host cells comprising the nucleic acids. Also provided are methods of making such common light chain bispecific antibodies.

Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.

Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Abstract: Provided herein are phosphorylated Dicer 1 (pDicer1) antibodies, including those that selectively bind Serine 1728 and/or Serine 1852. Further provided herein are methods of treating cancer by administering the pDicer1 antibodies alone or in combination with other therapies.

Abstract: Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) in ribonucleic acid (RNA). The provided compositions include fusion proteins that can be used to edit RNA and detect m6A residues. Also provided are nucleic acids, vectors, constructs, host cells, and transgenic animals that encode or express such fusions proteins.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imagable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Abstract: Antimicrobial peptides and methods of use are provided.

Abstract: In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.

Abstract: Several embodiments of NO releasing structures are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The covalently modified polymer structures may be tailored to release nitric oxide in a controlled manner and are useful for treatment of various medical conditions.

Abstract: Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed.

Abstract: The present technology provides a carboxylic acid-modified nitrile-based copolymer latex including a carboxylic acid-modified nitrile-based copolymer including a conjugated diene-based monomer-derived unit, an ethylenic unsaturated nitrile-based monomer-derived unit, and an ethylenic unsaturated acid monomer-derived unit, wherein a pKa is 9.5 to 10.2, and the carboxylic acid-modified nitrile-based copolymer latex satisfies General Formulas 1 and 2.

Abstract: A method of making expanded fluoropolymer articles thermally bonds portions of expanded fluoropolymers together, without using an adhesive or crushing force, to produce stronger bonds at the joint between the expanded fluoropolymers than the bonds within the constituent expanded fluoropolymers. The method involves placing the portions of expanded fluoropolymers to be thermally bonded together in intimate contact with each other after wet-stretching the expanded fluoropolymers, and removing the wetting agent used to wet-stretch the expanded fluoropolymers, without subsequent expansion or stretching, to yield an expanded fluoropolymer article exhibiting unexpected and superior properties that can be used in a variety of medical and industrial applications.

Abstract: Disclosed is a process for operating a flashline heater and a flashline separation system. In the process and system, heat is supplied to the flashline heater by a first steam stage followed by a second steam stage. The steam pressure is controlled by a steam control system such that the pressure in the first steam stage is not equal to the pressure in the second steam stage. Also disclosed is a process for retrofitting a steam control system in a flashline separation system of an olefin polymerization system at least by changing the number of steam stages in the flashline separation system to include a first steam stage followed by a second steam stage, and changing the stream pressure control scheme such that the pressure in the first steam stage is independently controlled to be not equal to the pressure in the second steam stage.

Abstract: Provided herein is technology relating to polymerization and producing polymers and particularly, but not exclusively, to methods, systems, and compositions for producing articles using three-dimensional printing and for improving control of polymerization using a polymerization photoinhibitor having fast back reaction kinetics such as hexaarylbiimidazole compounds and bridged hexaarylbiimidazole compounds.

Abstract: A unimodal ethylene-co-1-butene copolymer that, when in melted form at 190 degrees Celsius, is characterized by a unique melt property space defined by combination of shear thinning and melt elasticity properties. A blown film consisting essentially of the unimodal ethylene-co-1-butene copolymer. A method of synthesizing the unimodal ethylene-co-1-butene copolymer. A method of making the blown film. A manufactured article comprising the unimodal ethylene-co-1-butene copolymer.

Abstract: A composition includes one or more copolymers of one or more vinylidene aromatic monomers and one or more unsaturated compounds containing nucleophilic groups, and the copolymer has on average about 0.01 to about 15.0 percent by weight of nucleophilic groups pendant from the copolymer. The copolymer is chain extended and/or branched by one or more copolymers of one or more vinylidene aromatic monomers and one or more unsaturated compounds having electrophilic groups, or a portion of the chains of the copolymer of one or more vinylidene aromatic monomers and one or more nucleophilic groups are crosslinked with other chains of the copolymer of one or more vinylidene aromatic monomers and one or more nucleophilic groups by ionic bonding of anions formed from the pendant nucleophilic groups with a metal cation having a valence of 2 or greater or complexation between pendant acid groups and metal oxides.

Abstract: To provide a modified vinylaromatic copolymer which can be used in production of copolymer rubber and which has reactivity and solubility, and a copolymer rubber material obtained therefrom, which simultaneously has processability, strength, and homogeneity. The modified vinylaromatic copolymer is a copolymer containing a structural unit (a) derived from a divinylaromatic compound and a structural unit (b) derived from a monovinylaromatic compound, wherein the structural unit (a) at least partially includes the following crosslinked structural unit (a1), and a terminal is modified by a modification group having at least one functional group selected from the group consisting of an amino group, a hydroxyl group, and an alkoxysilyl group.

Abstract: Provided herein is a curable fluoroelastomer composition including at least one fluoroelastomer comprising copolymerized units of a nitrile group-containing cure site monomer; a cure system comprising at least two different dihydrazides; and optionally at least one additive. Further provided are pre-forms comprising the curable composition, methods of curing the fluoroelastomer composition, compositions that are the product of curing the curable fluoroelastomer composition, and articles comprising the cured fluoroelastomer composition.

Abstract: A lighting device disclosed in an embodiment of the invention includes a substrate; a light emitting device disposed on the substrate; a resin layer sealing the light emitting device on the substrate; and a diffusion layer or a reflective substrate disposed on the resin layer, wherein the resin layer includes an oligomer, a monomer, and an additive, wherein the monomer includes IBOA (Iso-bornyl Acrylate), two or more dilution monomers and glycidyl methacrylate (GMA), the additive includes a photoinitiator and an amine-based light stabilizer, and in the oligomer and the monomer, the content of glycidyl methacrylate is 10 to 15%, and the resin layer may be a curable transparent resin cured by ultraviolet light.

Abstract: A lens having high quality even after long-term storage can be manufactured using a curable composition containing a compound represented by General Formula A, a compound represented by General Formula B, and a polymerization initiator, in which a ratio of a substance amount of the compound represented by General Formula B to a substance amount of the compound represented by General Formula A is 1 to 25 mol %. In the Formulas, each portion surrounded by a broken line of Ar11, Ar12, and Ar13 represents that each of the portions may form a fused ring; L1 and L2 each represent a single bond, —O—, or the like; Sp1 and Sp2 each represent a single bond or a divalent linking group; Pol1 and Pol2 each represent a polymerizable group; R3 to R6 each represent a substituent; and q, r, v, and w are each an integer of 0 to 4.

Abstract: A reactor system for producing modacrylic polymer having a main tank with at least one feed inlet, a mixing element inside the main tank, a secondary tank connected to the main tank with an overflow channel, a reaction terminator feed and a level meter for the secondary tank, an outlet at the bottom of the secondary tank, a level control valve that controls the outlet, a collection area connected to the outlet, and a control unit configured to control the level control valve to determine output amount to be transferred to the collection area from the secondary tank according to data received from the level meter in order to keep the level in the secondary tank constant. The temperature in the main tank and the secondary tank is continuously measured and the main tank and the secondary tank temperature difference is arranged such that it does not exceed ±5° C.

Abstract: Provided are Janus particles derived from natural starting materials, including starting materials that are plant-based and are not based on petrochemicals. Also provided are related compositions that include the disclosed particles, including emulsion compositions. Additionally provided are methods of synthesizing the disclosed Janus particles.

Abstract: A method for preparing a porous-polymer-modified metal carbon nanotube membrane includes: preparing an acidified carbon nanotube membrane; preparing a modification solution; heating the acidified carbon nanotube membrane in the modification solution and reacting to obtain a metal carbon nanotube membrane; conducting a polymerization reaction to obtain a crude polymer product; coating the metal carbon nanotube membrane with a polyethylene glycol diglycidyl ether (PEGDEG) solution; coating the metal carbon nanotube membrane with a porous polymer solution; and heating the metal carbon nanotube membrane to obtain the porous-polymer-modified metal carbon nanotube membrane. A porous-polymer-modified metal carbon nanotube membrane is prepared according to this method.